These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 19941160

  • 1. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM.
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [Abstract] [Full Text] [Related]

  • 2. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 3. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
    Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M.
    J Clin Oncol; 2008 Apr 01; 26(10):1671-6. PubMed ID: 18375896
    [Abstract] [Full Text] [Related]

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 01; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 5. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
    Dixon JM, Renshaw L, Langridge C, Young OE, McHugh M, Williams L, Murray J, Macaskill EJ, McCaig F, Dixon OM, Fallowfield LJ.
    Breast Cancer Res Treat; 2011 Feb 01; 125(3):741-9. PubMed ID: 20821047
    [Abstract] [Full Text] [Related]

  • 6. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 01; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 7. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 8. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
    Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C.
    Breast Cancer Res Treat; 2010 Feb 10; 120(1):127-34. PubMed ID: 20035381
    [Abstract] [Full Text] [Related]

  • 9. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 10. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 01; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 11. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M, Caruggi M, Colombo G.
    Clin Ther; 2004 Sep 01; 26(9):1546-61. PubMed ID: 15531017
    [Abstract] [Full Text] [Related]

  • 12. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Sep 01; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul 01; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 14. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 15. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A, Estévez LG, Lluch-Hernández A, Rodriguez-Lescure A, Rodriguez-Sanchez C, Sanchez-Rovira P.
    Adv Ther; 2011 Dec 01; 28(12):1045-58. PubMed ID: 22068628
    [Abstract] [Full Text] [Related]

  • 16. Are aromatase inhibitors superior to antiestrogens?
    Howell A, Buzdar A.
    J Steroid Biochem Mol Biol; 2005 Feb 01; 93(2-5):237-47. PubMed ID: 15860266
    [Abstract] [Full Text] [Related]

  • 17. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group.
    J Bone Miner Res; 2006 Aug 01; 21(8):1215-23. PubMed ID: 16869719
    [Abstract] [Full Text] [Related]

  • 18. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol; 2007 Mar 01; 25(7):820-8. PubMed ID: 17159195
    [Abstract] [Full Text] [Related]

  • 20. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug 01; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.